Description
CJC-1295 no DAC is a modified 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH), also identified in research literature as Modified GRF 1-29 or Mod GRF 1-29. Four amino acid substitutions in the native GHRH(1-29) sequence increase enzymatic resistance and improve receptor binding relative to unmodified GHRH — but without the albumin-binding Drug Affinity Complex that defines the DAC variant. The result is a compound with a half-life of approximately 30 minutes that activates the GHRH receptor (GHRHR) on pituitary somatotrophs, producing a defined, short-duration cAMP-mediated signaling window. Researchers use it specifically when pulsatile GHRH signaling — rather than sustained axis stimulation — is the experimental condition being studied.
Key Characteristics
- Binds GHRHR and activates a Gs-coupled cAMP cascade, stimulating GH synthesis and release from anterior pituitary somatotrophs — the same receptor and downstream signaling as endogenous GHRH, but with improved enzymatic stability
- Half-life of approximately 30 minutes — shorter than Sermorelin (also a short-acting GHRH analog) but with a modified sequence that improves resistance to dipeptidyl aminopeptidase IV degradation, which is the primary enzyme responsible for rapid GHRH clearance
- The short half-life makes it the preferred format for pulsatile signaling research — studies examining GH pulse amplitude, frequency, and pattern require a compound that clears between pulses, preserving the dynamic structure researchers are measuring
- Does not bind albumin and does not produce sustained GHRH receptor engagement — researchers requiring longer observation windows should use the DAC variant instead
- Frequently combined with ghrelin receptor agonists such as Ipamorelin in dual-pathway models; standalone format preferred when single-pathway GHRH isolation is the study design goal
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. CJC-1295 no DAC is more susceptible to enzymatic degradation than the DAC variant once reconstituted. Reconstitute immediately before use and avoid repeated freeze-thaw cycles to maintain compound integrity.
FAQs
What is CJC-1295 no DAC?
CJC-1295 no DAC (Modified GRF 1-29) is a synthetic 29-amino-acid GHRH analog with four sequence modifications that improve enzymatic stability relative to native GHRH. It activates the GHRH receptor on pituitary somatotrophs and stimulates GH release through a cAMP-mediated cascade, with a half-life of approximately 30 minutes. It is used in pulsatile GH signaling research where short, defined GHRH receptor activation windows are required.
How does CJC-1295 no DAC differ from CJC-1295 with DAC?
The DAC variant carries an additional Drug Affinity Complex that allows covalent albumin binding after administration, extending its half-life to approximately 6–8 days. CJC-1295 no DAC clears in approximately 30 minutes and does not bind albumin. The two compounds ask fundamentally different research questions — no DAC for pulsatile dynamics, DAC for sustained GHRH receptor engagement, and longer observation studies.
How does CJC-1295 no DAC compare to Sermorelin in research models?
Both are short-acting GHRH analogs that activate GHRHR and stimulate pulsatile GH release. Sermorelin is a 29-amino-acid fragment matching the natural N-terminal GHRH sequence exactly, while CJC-1295 no DAC incorporates four amino acid substitutions designed to improve enzymatic stability. Researchers select between them based on whether endogenous sequence fidelity or improved degradation resistance is the more relevant variable for their study design.
